| Page 69 | Kisaco Research

Discuss how life sciences companies prepare for future patent disputes by refining early-stage litigation strategy, anticipating procedural risk, and strengthening internal readiness to improve outcomes.

Author:

John Cox

Partner
Barnes & Thornburg

With deep knowledge of issues facing the life sciences industry, John Cox counsels clients regarding their worldwide intellectual property rights and represents their patent interests when litigation arises, particularly regarding pharmaceutical, chemical, and biotechnology matters. John takes his role in protecting these important assets of life science innovators very seriously while approaching each matter with enthusiasm.


Through his ability to communicate effectively and succinctly, John advises on, develops, and carries out global IP strategies for the benefit of innovative companies, his clients, who are focused on developing core assets that save and improve the lives of patients. John enjoys leveraging his unique ability to put together targeted and enduring teams for each matter – paying close attention to each person’s strengths and skillsets and how they fit with one another, alongside his highly specialized experience and thoughtful and responsive nature.
John is intimately familiar with the pharmaceutical industry, having dealt with patent and IP subject matter ranging from brain chemistry, the gastrointestinal system, drug delivery systems and treatments of rare diseases and cancer to medical diagnostic methods, the generation of biofuel using bacteria, and processes for manufacturing chemicals and pharmaceutical products. He also has almost two decades of experience in Abbreviated New Drug Application (ANDA) cases, including pre-litigation investigations.

John offers guidance from the first step of a matter through to resolution, including all aspects of litigation. He has extensive experience related to discovery and motion practice, as well as in developing offensive and defensive strategies. He is well versed in dealing with complex subject matter and technical witnesses, such as inventors and experts.


John adeptly helps clients navigate the crossroads of foreign business practices and the complexities of U.S. patent practice, having worked with foreign pharmaceutical, chemical, and biotechnology companies throughout his career.

John Cox

Partner
Barnes & Thornburg

With deep knowledge of issues facing the life sciences industry, John Cox counsels clients regarding their worldwide intellectual property rights and represents their patent interests when litigation arises, particularly regarding pharmaceutical, chemical, and biotechnology matters. John takes his role in protecting these important assets of life science innovators very seriously while approaching each matter with enthusiasm.


Through his ability to communicate effectively and succinctly, John advises on, develops, and carries out global IP strategies for the benefit of innovative companies, his clients, who are focused on developing core assets that save and improve the lives of patients. John enjoys leveraging his unique ability to put together targeted and enduring teams for each matter – paying close attention to each person’s strengths and skillsets and how they fit with one another, alongside his highly specialized experience and thoughtful and responsive nature.
John is intimately familiar with the pharmaceutical industry, having dealt with patent and IP subject matter ranging from brain chemistry, the gastrointestinal system, drug delivery systems and treatments of rare diseases and cancer to medical diagnostic methods, the generation of biofuel using bacteria, and processes for manufacturing chemicals and pharmaceutical products. He also has almost two decades of experience in Abbreviated New Drug Application (ANDA) cases, including pre-litigation investigations.

John offers guidance from the first step of a matter through to resolution, including all aspects of litigation. He has extensive experience related to discovery and motion practice, as well as in developing offensive and defensive strategies. He is well versed in dealing with complex subject matter and technical witnesses, such as inventors and experts.


John adeptly helps clients navigate the crossroads of foreign business practices and the complexities of U.S. patent practice, having worked with foreign pharmaceutical, chemical, and biotechnology companies throughout his career.

Author:

Lauren Baker

Associate
Barnes & Thornburg

Lauren Baker

Associate
Barnes & Thornburg

Discuss the strategic deployment of European litigation venues for US pharma companies, including the UK High Court litigation, UPC proceedings and EPO oppositions, and compare the impacts on injunction risk, cost exposure, and global settlement dynamics.

Author:

Oliver Laing

Partner
Potter Clarkson

Oliver Laing

Partner
Potter Clarkson

Author:

Mark Didmon

Partner
Potter & Clarkson

Mark Didmon

Partner
Potter & Clarkson

Examine how branded and biosimilar companies build, litigate, and defend formulation and delivery patents as core composition claims expire and these assets become the last line of exclusivity.

Author:

Lachlan Campbell-Verduyn

Partner
Patterson Belknap

Lachlan Campbell-Verduyn

Partner
Patterson Belknap

Author:

Andrew Cohen

Partner
Patterson Belknap

Andrew Cohen

Partner
Patterson Belknap
 

Olivier Marchand

Regenerative Agriculture Manager
Nestlé

Olivier Marchand is Regenerative Agriculture Manager at Nestlé, with over 20 years of experience driving sustainability, quality, and responsible practices across value chains.

With a strong background in purchasing, quality assurance, and agriculture, he has worked across Europe, Africa, Latin America, and Asia, bringing a global and cross-cultural perspective. He focuses on strengthening traceability, sustainability, and trust, helping meet growing consumer expectations around product origin, production methods, and social responsibility.

Olivier Marchand

Regenerative Agriculture Manager
Nestlé

Olivier Marchand

Regenerative Agriculture Manager
Nestlé

Olivier Marchand is Regenerative Agriculture Manager at Nestlé, with over 20 years of experience driving sustainability, quality, and responsible practices across value chains.

With a strong background in purchasing, quality assurance, and agriculture, he has worked across Europe, Africa, Latin America, and Asia, bringing a global and cross-cultural perspective. He focuses on strengthening traceability, sustainability, and trust, helping meet growing consumer expectations around product origin, production methods, and social responsibility.

 

Sébastien Roumegous

CEO
BIOSPHERES

Sébastien Roumegous is a soil specialist and impact entrepreneur focused on scaling regenerative agriculture. As CEO of BIOSPHERES, Europe’s leading regenerative agriculture company, he supports businesses and public actors in transitioning toward high-performing, ecosystem-restoring farming systems.

Sébastien Roumegous

CEO
BIOSPHERES

Sébastien Roumegous

CEO
BIOSPHERES

Sébastien Roumegous is a soil specialist and impact entrepreneur focused on scaling regenerative agriculture. As CEO of BIOSPHERES, Europe’s leading regenerative agriculture company, he supports businesses and public actors in transitioning toward high-performing, ecosystem-restoring farming systems.

With over 15 years of experience across 22 countries and 200,000 hectares in transition, his work combines technical expertise with a pragmatic, field-driven approach to improve soil health, biodiversity, and farmers’ livelihoods. Raised in a farming environment in southern France, he brings a grounded, results-oriented perspective to large-scale agricultural transformation. He recently published his first book on regenerative agriculture.